Format

Send to

Choose Destination
Br J Haematol. 2016 Nov;175(3):410-418. doi: 10.1111/bjh.14241. Epub 2016 Jul 5.

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.

Author information

1
Department of Haematology, Rigshospitalet, Copenhagen, Denmark. christian.winther.eskelund.01@regionh.dk.
2
Department of Oncology, Oslo University Hospital, Oslo, Norway.
3
Department of Oncology, Lund University Hospital, Lund, Sweden.
4
Department of Haematology, Helsinki University Central Hospital, Helsinki, Finland.
5
Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
6
Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
7
Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
8
Department of Haematology, Karolinska Institute, Stockholm, Sweden.
9
Department of Haematology, Aarhus University Hospital, Aarhus, Denmark.
10
Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.
11
Section of Haematology and Coagulation Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
12
Department of Pathology, Lund University Hospital, Lund, Sweden.
13
Department of Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden.
14
Department of Pathology, Oslo University Hospital, Oslo, Norway.
15
Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland.
16
Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark.
17
Department of Health Sciences, University of Copenhagen, Copenhagen, Denmark.

Abstract

In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-therapy and autologous stem cell transplantation. One such strategy is the Nordic MCL2 regimen, developed by the Nordic Lymphoma Group. We here present the 15-year updated results of the Nordic MCL2 study after a median follow-up of 11·4 years: For all patients on an intent-to-treat basis, the median overall and progression-free survival was 12·7 and 8·5 years, respectively. The MCL International Prognostic Index (MIPI), biological MIPI, including Ki67 expression (MIPI-B) and the MIPI-B including mIR-18b expression (MIPI-B-miR), in particular, significantly divided patients into distinct risk groups. Despite very long response durations of the low and intermediate risk groups, we observed a continuous pattern of relapse and the survival curves never reached a plateau. In conclusion, despite half of the patients being still alive and 40% in first remission after more than 12 years, we still see an excess disease-related mortality, even among patients experiencing long remissions. Even though we consider the Nordic regimen as a very good choice of regimen, we recommend inclusion in prospective studies to explore the benefit of novel agents in the frontline treatment of MCL.

KEYWORDS:

Mantle Cell Lymphoma; Non-Hodgkin Lymphoma; clinical trials; high dose therapy

PMID:
27378674
DOI:
10.1111/bjh.14241
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley Icon for Norwegian BIBSYS system
Loading ...
Support Center